Recent investments in nuclear infrastructure focus on the growing demand for medical isotopes, including Actinium-225, the focus of our April newsletter.
For those unfamiliar, Actinium-225 is a rare alpha-emitting radionuclide in ultra-high demand for research and development of next-generation precision cancer treatments.
"Actinium-225 is the miracle drug we've been wishing for," writes Serva CEO Ian Horvath. "Actinium-225 is a radioisotope that emits alpha particles that deliver short-range but high-energy radiation, offering an ideal combination that kills cancer cells without harming nearby healthy cells."
